Thermo Fisher Scientific reported strong fiscal second-quarter 2026 results, with revenue growing 10% to $11.99 billion and adjusted earnings per share rising 13% to $6.03. The company expanded its portfolio with new analytical instruments including the Orbitrap Tribrid Apex Mass Spectrometer, and its Life Sciences Solutions segment saw reported revenue climb 13% year over year. The Analytical Instruments segment returned to growth after two years of muted demand, while adjusted operating margin expanded to 22.8%. Several analysts raised their price targets, with RBC Capital lifting its target to $580 from $490, and management raised full-year revenue guidance to a range of $47.4 billion to $48.1 billion. Hedge fund ownership increased modestly from 113 funds in the fourth quarter of 2025 to 115 funds in the first quarter of 2026, though the stock trades at roughly 22 times forward earnings, a 15.45% premium to the sector.
Thermo Fisher Scientific IncStrong Q2 results with revenue and EPS growth, raised guidance, and analyst price target hikes.